Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RONALD J OUDIZ

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1316957228
CMS profile
332283
Location
TORRANCE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$93,645.73

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RONALD J OUDIZ

NPI 1316957228 · CMS profile ID 332283

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

TORRANCE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316957228?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RONALD J OUDIZ, NPI 1316957228, CMS profile ID 332283. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316957228?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RONALD J OUDIZ, NPI 1316957228, CMS profile ID 332283. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316957228?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RONALD J OUDIZ, NPI 1316957228, CMS profile ID 332283, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1316957228?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $93,645.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–108 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $22.0602/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101611859 CMS
SCPHARMACEUTICALS INC. $23.5402/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132247376 CMS
Janssen Pharmaceuticals, Inc $28.4302/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943080 CMS
Merck Sharp & Dohme LLC $1,830.0002/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141767547 CMS
Kiniksa Pharmaceuticals International, plc $23.2601/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154873358 CMS
Novartis Pharmaceuticals Corporation $26.7301/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087227901 CMS
Actelion Pharmaceuticals US, Inc. $8,100.0001/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078872790 CMS
Janssen Pharmaceuticals, Inc $24.7301/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943028 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $131,597.66 194
PY2020 $23,483.08 27
PY2021 $66,979.15 70
PY2022 $91,152.59 113
PY2023 $89,167.90 156
PY2024 $93,645.73 108
PY2025 $121,291.40 124

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $352,672.50 30
PY2024 Principal investigator $525,340.29 24
PY2023 Recipient $982.50 1
PY2023 Principal investigator $351,006.60 32
PY2022 Principal investigator $534,694.76 32
PY2021 Principal investigator $160,906.11 28
PY2020 Recipient $562.50 1
PY2020 Principal investigator $27,380.34 14
PY2019 Recipient $5,281.43 18
PY2019 Principal investigator $18,185.00 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $116,744.44 12/31/2025 Non-covered Recipient Entity
Harbor UCLA Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III o No dispute reported 06/30/2026 1232917577
Principal investigator 1 Merck Sharp & Dohme LLC $19,869.90 12/31/2025 Non-covered Recipient Entity
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038 No dispute reported 06/30/2026 1232933814
Principal investigator 1 Merck Sharp & Dohme LLC $90,059.73 12/31/2025 Non-covered Recipient Entity
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232938428
Principal investigator 1 Janssen Research & Development, LLC $501.00 12/15/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441113
Principal investigator 1 Merck Sharp & Dohme LLC $14,000.00 12/15/2025 Non-covered Recipient Entity
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038 No dispute reported 06/30/2026 1232933812
Principal investigator 1 Merck Sharp & Dohme LLC $14,344.50 12/11/2025 Non-covered Recipient Entity
Harbor UCLA Medical Center
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH No dispute reported 06/30/2026 1232917669
Principal investigator 1 Janssen Research & Development, LLC $200.00 12/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441218
Principal investigator 1 Janssen Research & Development, LLC $14,672.00 12/01/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441203
Principal investigator 1 Janssen Research & Development, LLC $16,038.00 12/01/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441236
Principal investigator 1 Janssen Research & Development, LLC $729.00 10/30/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441125
Principal investigator 1 Janssen Research & Development, LLC $200.00 10/06/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441242
Principal investigator 1 Janssen Research & Development, LLC $2,516.00 10/02/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441161
Principal investigator 1 Janssen Research & Development, LLC $1,458.00 09/04/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441152
Principal investigator 1 Janssen Research & Development, LLC $100.00 07/28/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441119
Principal investigator 1 Janssen Research & Development, LLC $2,916.00 06/26/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441131
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 06/02/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441208
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 06/02/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441250
Principal investigator 1 Janssen Research & Development, LLC $1,787.00 05/26/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441191
Principal investigator 1 Janssen Research & Development, LLC $78.93 05/01/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441224
Principal investigator 1 Janssen Research & Development, LLC $6,958.00 04/28/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441106
Principal investigator 1 Merck Sharp & Dohme LLC $21,000.00 04/21/2025 Non-covered Recipient Entity
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on No dispute reported 06/30/2026 1232938670
Principal investigator 1 Janssen Research & Development, LLC $3,314.00 03/31/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441157
Principal investigator 1 Janssen Research & Development, LLC $8,662.00 03/10/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441146
Principal investigator 1 Janssen Research & Development, LLC $198.00 03/07/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441214
Principal investigator 1 Janssen Research & Development, LLC $6,584.00 03/03/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441174
Principal investigator 1 Janssen Research & Development, LLC $1,328.00 02/24/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441137
Principal investigator 1 Janssen Research & Development, LLC $200.00 02/24/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441196
Principal investigator 1 Janssen Research & Development, LLC $2,656.00 02/10/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441168
Principal investigator 1 Janssen Research & Development, LLC $1,458.00 01/27/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441254
Principal investigator 1 Janssen Research & Development, LLC $600.00 01/23/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL C
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441180